evidencebas
medicin
ebm
conscienti
explicit
judici
use
current
best
evid
make
decis
care
individu
patient
mean
integr
individu
clinic
expertis
bestavail
extern
clinic
evid
systemat
research
ebm
ask
question
find
apprais
relev
data
use
inform
everyday
clinic
practic
done
formul
clear
clinic
question
patient
problem
search
literatur
relev
clinic
articl
evalu
evid
valid
use
implement
use
find
clinic
practic
central
pillar
ebm
random
control
trial
rct
defin
clinic
trial
involv
least
one
test
treatment
one
control
treatment
concurr
enrol
followup
testand
controltr
group
treatment
administ
select
random
process
use
randomnumb
tabl
howev
often
sampl
size
small
assess
endpoint
mortal
one
need
systemat
review
literatur
metaanalysi
use
quantit
method
outcom
process
enabl
evid
classifi
five
level
subsequ
facilit
develop
five
grade
recommend
regard
treatment
option
maneuvr
receiv
grade
recommend
need
least
two
studi
provid
level
evid
support
intervent
larg
prospect
rct
unequivoc
result
low
risk
bia
metaanalysi
low
risk
bia
provid
level
evid
contrast
nonrandom
histor
control
studi
well
case
report
uncontrol
studi
expert
opinion
classifi
level
evid
allow
grade
e
recommend
screen
intens
care
unit
icu
literatur
use
ebm
principl
maneuvr
may
impact
infecti
morbid
mortal
classifi
common
maneuvr
accord
level
evid
grade
recommend
tabl
petro
kg
lowri
hkf
van
saen
jc
marshal
hand
hygien
never
shown
control
pneumonia
reduc
mortal
ventil
patient
random
trial
efficaci
hand
hygien
reduc
incid
infect
studi
six
nonrandom
two
random
trial
tabl
four
studi
rct
random
control
trial
pneumonia
endpoint
none
hand
wash
impact
studi
demonstr
impact
mortal
hand
hygien
cohort
studi
semmelwei
classic
studi
show
surviv
benefit
hand
disinfect
women
admit
deliveri
mortal
child
bed
fever
significantli
reduc
follow
implement
hand
wash
chlorin
lime
compar
histor
control
group
doctor
wash
hand
studi
often
refer
prime
evid
effect
hand
disinfect
recent
experi
corona
viru
infect
caus
sever
acut
respiratori
syndrom
sar
toronto
demonstr
rigor
implement
tradit
infect
control
measur
control
outbreak
highlevel
pathogen
similar
streptococcu
pyogen
seen
year
ago
vienna
data
avail
effect
isol
protect
cloth
care
equip
environ
rate
bacteri
pneumonia
associ
mortal
ventil
patient
five
tradit
infect
control
measur
target
control
transmiss
microorgan
via
hand
carrier
import
impact
overestim
optim
infect
control
polici
reduc
infect
due
microorgan
acquir
unit
ie
secondari
endogen
exogen
infect
fail
influenc
primari
endogen
infect
due
microorgan
present
admiss
flora
type
infect
major
infect
problem
icu
vari
chapter
posit
therapi
sever
ill
patient
requir
ventil
often
treat
supin
posit
lead
segment
collaps
basal
atelectasi
impair
clearanc
secret
factor
increas
risk
pneumonia
treat
patient
special
rotat
bed
patient
continu
rotat
around
longitudin
axi
could
theoret
help
prevent
pneumonia
one
posit
metaanalysi
six
rct
show
signific
reduct
pneumonia
patient
receiv
rotat
therapi
therebi
support
kinet
therapi
infect
control
maneuvr
six
studi
five
perform
surgic
neurolog
patient
sixth
trial
reduct
pneumonia
perform
nonsurg
icu
patient
recent
rct
mix
icu
popul
support
conclus
metaanalysi
rotat
therapi
requir
special
bed
may
associ
increas
cost
semirecumb
posit
although
gener
throat
consid
intern
sourc
potenti
pathogen
microorgan
ppm
caus
pneumonia
peopl
believ
aspir
ppm
carri
stomach
may
play
role
pathogenesi
pneumonia
socal
stomachlung
rout
base
upon
concept
ventil
patient
semirecumb
posit
thought
benefici
effect
reduc
incid
reflux
aspir
stomach
wherebi
pneumonia
ventil
patient
could
prevent
maneuvr
investig
two
rct
tabl
first
studi
show
ventil
patient
semirecumb
posit
lead
signific
reduct
pneumonia
mortal
rate
howev
ident
test
control
group
howev
patient
underw
abdomin
neurosurgeri
patient
refractori
shock
patient
readmit
icu
within
month
exclud
second
rct
publish
abstract
form
fail
confirm
result
differ
pneumonia
rate
mortal
subglott
drainag
stasi
saliva
contamin
potenti
pathogen
cuff
endotrach
tube
increas
risk
aspir
pneumonia
remov
prevent
salivari
stasi
use
continu
aspir
via
special
design
endotrach
tube
thought
prevent
pneumonia
intervent
subglott
drainag
evalu
four
rct
tabl
three
studi
perform
mix
icu
popul
requir
ventil
h
fourth
studi
cardiac
surgeri
patient
result
trial
consist
two
studi
show
signific
reduct
pneumonia
two
fail
show
impact
pneumonia
ventil
metaanalysi
four
studi
show
significantli
reduc
rel
risk
pneumonia
due
subglott
drainag
rel
risk
rr
differ
mortal
test
control
group
studi
although
special
design
tube
suction
equip
expens
techniqu
suggest
cost
effect
theoret
ground
recent
work
indic
subglott
drainag
caus
sever
tracheal
mucos
damag
level
suction
port
enter
feed
total
parenter
nutrit
shown
harm
term
higher
infect
rate
liver
impair
prompt
desir
enter
feed
icu
patient
quickli
possibl
thought
essenti
gut
anatomi
physiolog
order
prevent
loss
mucosa
integr
subsequ
transloc
addit
sever
nutrient
ad
enter
feed
shown
influenc
immunolog
tabl
show
signific
reduct
overal
infect
rate
although
specif
consid
pneumonia
reduct
mortal
either
metaanalys
surgic
patient
seem
benefit
medic
two
recent
larg
rct
mortal
rate
significantli
higher
subgroup
receiv
immunonutrit
specul
ad
arginin
might
detriment
immun
system
steroid
high
dose
steroid
given
septic
patient
thought
benefici
three
reason
steroid
effect
suppress
gener
inflamm
due
microorgan
toxin
shown
significantli
reduc
septic
shock
earli
mortal
within
h
significantli
reduc
mortal
caus
particular
invas
infect
includ
mening
typhoid
pneumocysti
carinii
pneumonia
major
perceiv
side
effect
highdos
steroid
associ
immun
suppress
subsequ
risk
superinfect
inde
two
metaanalys
show
trend
toward
increas
mortal
secondari
infect
patient
receiv
steroid
next
logic
step
would
combin
steroid
select
decontamin
digest
tract
sdd
wherebi
perceiv
harm
effect
steroid
could
abolish
way
earli
surviv
benefit
steroid
could
preserv
keep
patient
free
secondari
infect
use
sdd
antiinflammatori
mediat
almost
rct
test
hypothesi
modul
endogen
host
inflammatori
respons
improv
surviv
patient
clinic
diagnosi
sepsi
result
frustrat
new
agent
introduc
clinic
practic
pool
data
studi
use
monoclon
antibodi
neutral
tumour
necrosi
factor
demonstr
statist
signific
reduct
mortal
aggreg
three
complet
studi
use
recombin
receptor
antagonist
neutral
also
show
absolut
mortal
reduct
zeni
et
al
show
combin
result
complet
trial
independ
therapeut
agent
employ
demonstr
statist
signific
overal
reduct
allcaus
mortal
question
whether
small
clinic
benefit
suffici
import
justifi
clinic
use
therapi
given
cost
potenti
toxic
agent
involv
immunoglobulin
polyclon
intraven
immunoglobulin
ivig
significantli
reduc
mortal
use
extra
treatment
option
sepsi
septic
shock
overal
mortal
reduc
patient
receiv
polyclon
ivig
confid
interv
ci
two
highqual
trial
polyclon
ivig
rr
overal
mortal
ci
wide
ci
howev
trial
small
total
evid
insuffici
support
robust
conclus
benefit
adjunct
therapi
monoclon
ivig
remain
experiment
level
evid
prompt
grade
c
recommend
usag
activ
protein
c
drotrecogin
activ
recombin
human
activ
protein
c
thought
antiinflammatori
antithrombot
profibrinolyt
properti
one
larg
rct
patient
mortal
rate
placebo
group
drotrecogin
group
translat
absolut
reduct
risk
death
incid
seriou
bleed
higher
drotrecogin
activ
group
placebo
group
level
evid
grade
b
recommend
rct
patient
conclud
use
lower
tidal
volum
mlkg
mechan
ventil
compar
tradit
tidal
volum
mlkg
mortal
lower
vs
absolut
mortal
reduct
ci
patient
need
receiv
low
tidal
volum
ventil
save
life
patient
intens
insulin
therapi
reduc
mortal
intens
care
p
blood
glucos
level
maintain
mmoll
absolut
mortal
reduct
ci
translat
patient
need
insulin
therapi
prevent
death
tabl
evidencebas
medicin
intens
care
unit
select
decontamin
digest
tract
philosophi
sdd
discuss
chapter
efficaci
sdd
studi
rct
nine
metaanalys
rct
sdd
metaanalys
show
rate
infect
particularli
pneumonia
significantli
reduc
independ
method
use
diagnos
pneumonia
full
fourcompon
protocol
sdd
mix
icu
popul
requir
minimum
h
ventil
analys
studi
applic
full
fourcompon
protocol
reduc
morbid
due
pneumonia
mortal
latest
sdd
trial
random
icu
patient
previou
trial
studi
approxim
patient
largest
singl
studi
yet
undertaken
primari
endpoint
mortal
oppos
infecti
morbid
risk
mortal
significantli
reduc
unit
sdd
administ
patient
previou
trial
patient
random
unit
therefor
half
popul
respect
icu
decontamin
therefor
possibl
control
patient
although
receiv
sdd
benefit
intervent
expos
lower
risk
microbi
acquisit
carriag
infect
subsequ
mortal
dilut
risk
due
control
group
present
decontamin
patient
time
unit
term
contamin
bia
design
latest
trial
avoid
type
bia
may
explain
highest
report
mortal
reduct
date
absolut
reduct
mortal
recent
second
rct
larg
sampl
size
found
ident
mortal
reduct
mean
patient
need
receiv
sdd
prevent
death
main
concern
liber
use
antibiot
emerg
resist
antimicrobi
resist
subsequ
superinfect
emerg
within
year
launch
new
parenter
antibiot
enter
antibiot
polymyxin
tobramycin
ad
success
decontamin
achiev
organ
may
becom
resist
parenter
antibiot
gut
erad
chapter
recent
metaanalysi
trial
compris
patient
cover
period
year
clinic
investig
neither
superinfect
outbreak
multiresist
bacteria
observ
agenc
health
research
qualiti
us
depart
health
human
servic
report
sdd
use
regular
surveil
cultur
appli
past
suspens
cheap
easi
implement
costeffect
sdd
properli
assess
cost
hardli
major
concern
maneuvr
euro
day
reduc
pneumonia
mortal
without
antimicrobi
resist
emerg
unselect
icu
patient
current
five
maneuvr
control
mortal
publish
within
last
year
twentyfirst
centuri
tabl
four
assess
one
rct
specif
subset
maneuvr
grade
recommend
agenc
health
research
qualiti
us
depart
health
human
servic
applic
type
patient
sdd
addit
sdd
control
resist
becom
major
issu
centuri
evidencebas
medicin
intens
care
unit
